- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
PI3KCB Antibody (C-term)Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP8017b | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
PI3KCB Antibody (C-term) - Product info | |
| Application | WB, IHC
|
| Primary Accession | P42338 |
| Reactivity | Human |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 122762 Da |
PI3KCB Antibody (C-term) - Additional info | |
| Gene ID 5291 | |
| Other Names PIK3CB; PIK3C1; Phosphatidylinositol 4, 5-bisphosphate 3-kinase catalytic subunit beta isoform; Phosphatidylinositol 4, 5-bisphosphate 3-kinase 110 kDa catalytic subunit beta | |
| Target/Specificity This PI3KCB antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 721~751 amino acids from the C-terminal region of human PI3KCB. | |
| Dilution WB~~1:100~500WB~~1:1000 IHC~~1:10~50 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions PI3KCB Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. | |
PI3KCB Antibody (C-term) - Protein Information | |
| Name PIK3CB | |
| Synonyms PIK3C1 | |
| Function Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns (Phosphatidylinositol), PtdIns4P (Phosphatidylinositol 4- phosphate) and PtdIns(4,5)P2 (Phosphatidylinositol 4,5- bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Involved in the activation of AKT1 upon stimulation by G-protein coupled receptors (GPCRs) ligands such as CXCL12, sphingosine 1-phosphate, and lysophosphatidic acid. May also act downstream receptor tyrosine kinases. Required in different signaling pathways for stable platelet adhesion and aggregation. Plays a role in platelet activation signaling triggered by GPCRs, alpha-IIb/beta-3 integrins (ITGA2B/ ITGB3) and ITAM (immunoreceptor tyrosine-based activation motif)-bearing receptors such as GP6. Regulates the strength of adhesion of ITGA2B/ ITGB3 activated receptors necessary for the cellular transmission of contractile forces Required for platelet aggregation induced by F2 (thrombin) and thromboxane A2 (TXA2). Has a role in cell survival. May have a role in cell migration. Involved in the early stage of autophagosome formation. Modulates the intracellular level of PtdIns3P (Phosphatidylinositol 3-phosphate) and activates PIK3C3 kinase activity. May act as a scaffold, independently of its lipid kinase activity to positively regulate autophagy. May have a role in insulin signaling as scaffolding protein in which the lipid kinase activity is not required. May have a kinase-independent function in regulating cell proliferation and in clathrin-mediated endocytosis. Mediator of oncogenic signal in cell lines lacking PTEN. The lipid kinase activity is necessary for its role in oncogenic transformation. Required for the growth of ERBB2 and RAS driven tumors | |
| Cellular Location Cytoplasm. Nucleus. Note=Interaction with PIK3R2 is required for nuclear localization and export | |
| Tissue Location Expressed ubiquitously. | |
PI3KCB Antibody (C-term) - Related products
AP8017b: PI3KCB Antibody (C-term)
AP8017d: PIK3CB Antibody (N-term S139)
RI13995: PIK3CB predesign siRNA
PI3KCB Antibody (C-term) - Application data
-
PI3KCB Antibody (C-term K727) (Cat. #AP8017b) western blot analysis in CEM cell line lysates (35ug/lane).This demonstrates the PI3KCB antibody detected the PI3KCB protein (arrow).
-
Formalin-fixed and paraffin-embedded human prostata carcinoma tissue reacted with PI3KCB antibody (C-term), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.
PI3KCB Antibody (C-term) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Protein kinases are enzymes that transfer a phosphate group from a phosphate donor, generally the g phosphate of ATP, onto an acceptor amino acid in a substrate protein. By this basic mechanism, protein kinases mediate most of the signal transduction in eukaryotic cells, regulating cellular metabolism, transcription, cell cycle progression, cytoskeletal rearrangement and cell movement, apoptosis, and differentiation. With more than 500 gene products, the protein kinase family is one of the largest families of proteins in eukaryotes. The family has been classified in 8 major groups based on sequence comparison of their tyrosine (PTK) or serine/threonine (STK) kinase catalytic domains.
REFERENCES
Brock, C., et al., J. Cell Biol. 160(1):89-99 (2003). Kossila, M., et al., Diabetes Care 26(1):179-182 (2003). Yart, A., et al., J. Biol. Chem. 277(24):21167-21178 (2002). Ueki, K., et al., Proc. Natl. Acad. Sci. U.S.A. 99(1):419-424 (2002). Sotsios, Y., et al., J. Immunol. 163(11):5954-5963 (1999).